Early deaths and primary graft failures in CB transplant recipients
Patient no. . | No. of cells before freezing, × 107/kg . | No. of HLA matches* . | Diagnosis . | Outcomes . |
|---|---|---|---|---|
| Early deaths | ||||
| 292 | 1.63 | 5/6 | AML (Rel) | Death due to MOF at d27 |
| 372 | 2.25 | 4/6 | ALL (CR2) | Death due to bacterial pneumonia at d13 |
| 377 | 3.66 | 4/6 | ALL (Rel) | Death due to VOD at d18 |
| Primary engraftment failures | ||||
| 314 | 2.71 | 3/6 | ALL (CR1) | Autologous recovery at d52, and survival in CR for 1651 d |
| 362 | 2.43 | 4/6 | AML (PIF) | Relapse at d54, and death at d368 due to bacterial pneumonia |
| 422 | 2.27 | 4/6 | CML (BC) | Death due to fungal pneumonia at d48 |
| 427 | 2.10 | 3/6 | CML (CP2) | Autologous recovery at d29, and survival in molecular CR for 322 d |
| 439 | 3.44 | 5/6 | ALL (CR1) | Second CBT at d33, survival in remission for 182 d |
Patient no. . | No. of cells before freezing, × 107/kg . | No. of HLA matches* . | Diagnosis . | Outcomes . |
|---|---|---|---|---|
| Early deaths | ||||
| 292 | 1.63 | 5/6 | AML (Rel) | Death due to MOF at d27 |
| 372 | 2.25 | 4/6 | ALL (CR2) | Death due to bacterial pneumonia at d13 |
| 377 | 3.66 | 4/6 | ALL (Rel) | Death due to VOD at d18 |
| Primary engraftment failures | ||||
| 314 | 2.71 | 3/6 | ALL (CR1) | Autologous recovery at d52, and survival in CR for 1651 d |
| 362 | 2.43 | 4/6 | AML (PIF) | Relapse at d54, and death at d368 due to bacterial pneumonia |
| 422 | 2.27 | 4/6 | CML (BC) | Death due to fungal pneumonia at d48 |
| 427 | 2.10 | 3/6 | CML (CP2) | Autologous recovery at d29, and survival in molecular CR for 322 d |
| 439 | 3.44 | 5/6 | ALL (CR1) | Second CBT at d33, survival in remission for 182 d |
AML indicates acute myelogenous leukemia; Rel, relapse; MOF, multi-organ failure; ALL, acute lymphoblastic leukemia; CR2, second remission; VOD, veno-occlusive disease; CR1, first remission; PIF, primary induction failure; CML, chronic myelogenous leukemia; BC, blastic crisis; and CP2, second chronic phase.
HLA-A and HLA-B antigens were identified by serologic typing and HLA-DRB1 alleles were determined by high-resolution molecular typing